Ordination Dr. Michael Würtz Facharzt für Lungenkrankheiten
- Address
- Landstrasse 70, 4020 Linz, Austria
Ordination Dr. Michael Würtz - Pulmonary Disease Specialist
Dr. Michael Würtz's pulmonary practice specializes in advanced research and treatment of chronic respiratory conditions, with particular emphasis on chronic obstructive pulmonary disease. The center is actively involved in clinical investigations evaluating novel therapeutic interventions for patients requiring complex maintenance therapy regimens.
- Chronic Obstructive Pulmonary Disease (COPD) management and research
- Advanced triple therapy combinations including ICS, LABA, and LAMA medications
- COPD exacerbation prevention and add-on therapeutic strategies
The practice contributes to pivotal studies assessing long-term efficacy and safety of emerging bronchodilator and anti-inflammatory agents. Dr. Würtz's research participation focuses on optimizing maintenance therapy protocols for patients with moderate to severe COPD, particularly evaluating novel dry powder inhaler formulations designed to reduce exacerbation rates when added to standard triple combination therapy.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Chiesi Farmaceutici S.p.A.2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 152 other sites in Austria
Therapeutic Area Benchmark — Austria
Select a therapeutic area to compare against other sites in Austria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Austria
Market Share
Country: Austria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Ordination Dr. Michael Würtz Facharzt für Lungenkrankheiten
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety Evaluation of Tanimilast (CHF6001) as an Add-On to Triple Therapy in Patients with Chronic Obstructive Pulmonary Disease and Chronic Bronchitis | Chiesi Farmaceutici S.p.A. | Phase III | Not Recruiting | Jun 2021 | Jun 2025 |
IMP list
lock Showing 1 of 2 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Tanimilast | 2 | Unknown | 2021-06-16 | 2021-06-17 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.